Long-term course of interferon-treated chronic hepatitis C

Journal of Hepatology

Volumn 28, Issue 4, 1998, Pages 531-537

  Cammà, Calogero ^a   Di Marco, Vito ^b   Lo Iacono, Oreste ^b   Almasio, Piero ^b   Giunta, Marco ^b   Fuschi, Patrizia ^b   Vaccaro, Alessandra ^b   Fabiano, Carmelo ^b   Magrin, Silvio ^b   Di Stefano, Rosa ^b   Bonura, Celestino ^b   Pagliaro, Luigi ^b   Craxì, Antonio ^b  

^a CNR   (Italy)

^b NONE

Author keywords

Cohort study; Hepatitis C; Interferon; Long term course

Indexed keywords

ALPHA INTERFERON;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; ELECTROIMMUNOASSAY; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; LIVER BIOPSY; LIVER DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RELAPSE; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT PLANNING;

EID: 0031972388     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80274-2     Document Type: Article

References (31)

1. Tiné F., Magrin S., Craxì A., Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomized clinical trials. J Hepatol. 13:1991;192-199.
2. Poynard T., Leroy V., Cohard M., Thevenot T., Mathurin P., Opolon P., et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 24:1996;778-789.
3. Niederau C., Heintges T., Häussinger D. Treatment of chronic NANB and C hepatitis with α-interferon: an analysis of the literature. Hepatogastroenterology. 43:1996;1544-1556.
4. Craxì A., Di Marco V., Almasio P. Hepatic hepatitis C virus RNA in chronic hepatitis C [letter]. Ann Intern Med. 124:1996;72.
5. Chemello L., Cavalletto L., Casain C., Bonetti P., Bernardinello E., Pontisso P. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C. Ann Intern Med. 124:1996;1058-1060.
6. Cammà C., Giunta M., Linea C., Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. J Hepatol. 26:1997;1187-1199.
7. Herson J. The use of surrogate endpoints in clinical trials (an introduction to a series of four papers). Stat Med. 8:1989;403-404.
8. Seeff L.B., Buskell-Bales Z., Wright E.C., Durako S.J., Alter H.J., Ibert F.L. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med. 327:1992;1906-1911.
9. Craxì A., Di Marco V., Lo Iacono O., Almasio P., Bruno R., Cammà C., et al. Transfusion-associated chronic hepatitis C: alpha-n1 interferon for 6 vs. 12 months. J Hepatol. 24:1996;539-546.
10. Di Marco V., Lo Iacono O., Cammà C., Almasio P.L., Vaccaro A., et al. A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C. J Med Virol. 51:1997;17-24.
11. Yoshioka K., Kakumu S., Wakita T., Ishikawa T., Itoh Y., Takayanagi M., et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: relationship to genotypes of hepatitis C virus. Hepatology. 16:1992;293-299.
12. Magrin S., Craxì A., Fabiano C., Marino L., Fiorentino G., Lo Iacono O., et al. HCV viremia is more important than genotype as predictor of response to interferon in Sicily (southern Italy). J Hepatol. 49:1996;583-590.
13. Stuyver L., Rossau R., Wyseur A., Duhamel M., Vanderborght B., Van Heuverswyn H., et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol. 74:1993;1093-1203.
14. Knodell R.G., Ishak K., Black W., Chen T.S., Craig R., Kaplowitz N., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
15. Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V. Design and analysis of randomized clinical trials requiring prolonged observation. II. Analysis and examples. Br J Cancer. 35:1977;1-39.
16. Cox D.R. Regression models and life tables (with discussion). J R Statist Soc B. 34:1972;187-220.
17. SAS Technical report SAS/STAT Software: Changes & Enhancements. 1992;SAS Institute Inc, Cary, NC. Release 6.07.
18. Shindo M., Di Bisceglie A.M., Hoofnagle J.H. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon. Hepatology. 15:1992;1013-1016.
19. Lau J.Y., Davis G.L., Kniffen J., Qian K.P., Urdea M.S., Chan C.S., et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 341:1993;1501-1504.
20. Castillo I., Bartolome J., Navas S., Gonzalez S., Herrero M., Carreño V. Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. Hepatology. 19:1994;342-346.
21. Saracco G., Rosina F., Abate M.L., Chiandussi L., Gallo V., Cerutti E., et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-α2b. Hepatology. 18:1993;1300-1305.
22. Picciotto A., Bardellini E., Borzone S., Sinelli N., Bonanni P., Bruzzone B., et al. Virological and biochemical responses to interferon-alpha in chronic hepatitis C (letter). Lancet. 343:1994;54-55.
23. Carreño V., Gerken G., Trèpo C., Bar-Meier S., Desmet V., Ryff J.C. Four years of follow-up (LTFUP) of patients with chronic hepatitis C (CHC) treated with interferon-α-2a [abstract]. Hepatology. 22:1995;173.
24. Karino Y., Toyota J., Higashino K., Sato T., Ohmura T., Aso K., et al. Analysis of prognosis of patients with type C chronic hepatitis who were treated with interferon [abstract]. Hepatology. 22:1995;177.
25. Reichard O., Glaumann H., Frydén A., Norkrans G., Schvarcz R., Sönnerborg A., et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology. 21:1995;918-922.
26. Takahashi M., Yamada G., Tsugeno H., Endo H., Kishi F., Takatani M., et al. Long-term biochemical, virological and histological follow-up in patients with chronic hepatitis C treated with interferon [abstract]. Hepatology. 22:1995;174.
27. Morisco F., Tuccillo C., Sessa G., Iasevoli P., Forestieri M.C., Del Vecchio-Blanco G., et al. Can chronic HCV infection terminate in patients with chronic active hepatitis long-term responders to interferon therapy? [abstract]. Gastroenterology. 108:1995;1126.
28. Shindo M., Arai K., Sokawa Y., Okuno T. The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. Hepatology. 22:1995;418-425.
29. Shindo M., Arai K., Yoshihiro S., Okuno T. Hepatic hepatitis C virus RNA as a predictor of long-term response to interferon therapy. Ann Intern Med. 122:1995;586-591.
30. Pagliaro L., Craxì A., Cammá C., Tiné F., Di Marco V., Lo Iacono O., et al. Interferon-α for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology. 19:1994;820-828.
31. Nishiguchi S., Kuroki T., Nakatani S., Morimoto H., Takeda T., Nakajima S., et al. Randomized trial of effect of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 346:1995;1051-1055.